A Phase 3, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics, Safety and Tolerability, and Efficacy of TAK-771 in Japanese Subjects With Primary Immunodeficiency Diseases (PID)
Latest Information Update: 11 Oct 2024
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Registrational; Therapeutic Use
- Sponsors Takeda
- 05 Sep 2023 Status changed from active, no longer recruiting to completed.
- 30 May 2023 Planned End Date changed from 30 Apr 2023 to 31 Aug 2023.
- 30 May 2023 Planned primary completion date changed from 30 Apr 2023 to 31 Aug 2023.